Table 5.
Univariable analysis investigating the influence of epidemiological and clinical variables on the olfactory and gustatory dysfunction (OGD) resolution at T3.
| HR | 95%CI | p | |
|---|---|---|---|
| Age (years) | 0.98 | 0.96–1.01 | 0.147 |
| Sex (male vs female) | 0.8 | 0.4–1.4 | 0.454 |
| Seasonal influenza vaccination (yes vs no) | 2.0 | 1.0–4.0 | 0.070* |
| Smoking | |||
| Ex vs no | 1.4 | 0.7–2.9 | 0.338 |
| Yes vs no | 1.5 | 0.8–2.9 | 0.235 |
| General sign and symptoms (yes vs no) | 0.5 | 0.3–0.9 | 0.023* |
| Nasal obstruction (yes vs no) | 1.4 | 0.8–2.5 | 0.238 |
| Comorbidities (yes vs no) | 0.8 | 0.4–1.6 | 0.547 |
| Endocrine disorders (yes vs no) | 0.9 | 0.4–2.3 | 0.866 |
| Allergies (yes vs no) | 1.2 | 0.6–2.1 | 0.632 |
| Rhinorrhea (yes vs no) | 0.8 | 0.4–1.5 | 0.463 |
| SARS-CoV-2 IgG titer (AU/mL) | 0.9 | 0.6–1.6 | 0.801 |
| Log10 RNA (copies/mL) | 0.8 | 0.3–2.0 | 0.644 |
| VAS-O | 1.1 | 1.0–1.3 | 0.083 |
| VAS-G | 1.1 | 1.0–1.2 | 0.005* |
| HRS | 0.9 | 0.9–1.0 | 0.034* |
| CCS | 0.9 | 0.8–1.0 | 0.003* |
HR, Hazard Ratio; CI, Confidence Interval; VAS—O, Visual Analogue Scale – Olfactory; VAS-G, Visual Analogue Scale – Gustatory; HRS, Hyposmia Rating Scale; CCS, Chemosensory Complaint Score; * p < 0.05.